GE Healthcare



2020 Coding and Reimbursement Guide

Clariscan™ (gadoterate meglumine) injection for intravenous use

PRODUCT INDICATIONS AND USE:

CLARISCAN[™] (gadoterate meglumine) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine, and associated tissues in adult and pediatric patients to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Additional pediatric use information is approved for Guerbet LLC's Dotarem (gadoterate meglumine injection). However, due to Guerbet LLC's marketing exclusivity, this drug product is not labeled with that pediatric information.

IMPORTANT SAFETY INFORMATION ABOUT CLARISCAN™

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)

See full Prescribing Information for complete Boxed Warning.

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs.

- The risk for NSF appears highest among patients with:
 - Chronic, severe kidney disease (GFR <30 mL/min/1.73 m²), or
 - Acute kidney injury.
- Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at
 risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular
 filtration rate (GFR) through laboratory testing.
- For patients at highest risk for NSF, do not exceed the recommended Clariscan dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.

Contraindications

History of clinically important hypersensitivity reactions to Clariscan.

Warnings and precautions

• **Hypersensitivity reactions:** Anaphylactic and anaphylactoid reactions have been reported with gadoterate meglumine, involving cardiovascular, respiratory, and/or cutaneous manifestations. Some patients experienced circulatory collapse and died. In most cases, initial symptoms occurred within minutes of gadoterate meglumine administration and resolved with prompt emergencytreatment.

- Before Clariscan administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to Clariscan.
- Administer Clariscan only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, including personnel trained in resuscitation.

(Continued on following screen)

Clariscan™ (gadoterate meglumine) injection for intravenous use

- **Gadolinium retention:** Gadolinium is retained for months or years in several organs. The highest concentrations have been identified in the bone, followed by brain, skin, kidney, liver and spleen. The duration of retention also varies by tissue and is longest in bone. Linear GBCAs cause more retention than macrocyclic GBCAs.
 - Consequences of gadolinium retention in the brain have not been established. Adverse events involving multiple organ systems have been reported in patients with normal renal function without an established causal link to gadolinium retention.
- Acute kidney injury: In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred with the use of GBCAs. The risk of acute kidney injury may increase with increasing dose of the contrast agent; administer the lowest dose necessary for adequate imaging.
- **Extravasation and injection site reactions:** Ensure catheter and venous patency before the injection of Clariscan. Extravasation into tissues during Clariscan administration may result in tissue irritation.

Adverse reactions

- The most common adverse reactions (≥ 0.2%) associated with gadoterate meglumine in clinical trials were nausea, headache, injection site pain, injection site coldness and rash.
- Serious adverse reactions in the postmarketing experience have been reported with gadoterate meglumine. These serious adverse reactions include but are not limited to: arrhythmia, cardiac arrest, respiratory arrest, pharyngeal edema, laryngospasm, bronchospasm, coma and convulsion.

Use in specific populations

- **Pregnancy:** GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. The human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive. Because of the potential risks of gadolinium to the fetus, use Clariscan only if imaging is essential during pregnancy and cannot be delayed. Advise pregnant women of the potential risk of fetal exposure to GBCAs.
- Lactation: There are no data on the presence of gadoterate in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01 to 0.04% of the maternal gadolinium dose is present in breast milk.
- **Pediatric use:** The safety and efficacy of gadoterate meglumine at a single dose of 0.1 mmol/kg has been established in pediatric patients from 2 to 17 years of age based on clinical data in 133 pediatric patients 2 years of age and older. Adverse reactions in pediatric patients were similar to those reported in adults. No dosage adjustment according to age is necessary in pediatric patients. No cases of NSF associated with gadoterate meglumine or any other GBCA have been identified in pediatric patients age 6 years and younger. The safety of gadoterate meglumine has not been established in preterm neonates.

Additional pediatric use information is approved for Guerbet, LLC's Dotarem (gadoterate meglumine injection). However, due to Guerbet LLC's marketing exclusivity, this drug product is not labeled with that pediatric information.

Prior to Clariscan administration please read the <u>full Prescribing Information</u>, including the Black Box Warning and <u>patient Medication Guide</u>, for additional important safety information.

To report SUSPECTED ADVERSE REACTIONS, contact GE Healthcare at 800-654-0118 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see <u>Product Indications and Important Safety Information About Clariscan</u>, including Boxed Warning, and the <u>full Prescribing Information</u>, including <u>patient Medication Guide</u>.

Clariscan

Table of Contents

Important Safety Information About Clariscan
Introduction
Description and Indication5
2020 Coding and Reimbursement Guide5
Basics of Coding
Current Procedural Terminology (CPT [®]) Codes6
Healthcare Common Procedure Coding System (HCPCS)6
National Drug Codes (NDCs)6
Basics of Coverage
Medicare
Commercial/Private Payers
Medicaid7
Basics of Payment
Physician Offices and Independent Diagnostic Testing Facilities (IDTFs)
Hospital Outpatient Setting
2020 Coding and Reimbursement Information
HCPS
National Drug Codes (NDCs)
Reimbursement in the Physician Office/IDTF Setting11
Reimbursement in the Hospital Outpatient Setting11
Support for Clariscan
Reimbursement Hotline
Customer Service
Medical Affairs
Full Prescribing Information and Patient Medication Guide 13

CPT is a registered trademark of the American Medical Association.

Introduction

Description and Indications

Clariscan[™] (gadoterate meglumine) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine, and associated tissues in adult and pediatric patients to detect and visualize areas with disruption of the blood-brain barrier (BBB) and/or abnormal vascularity.¹

Please refer to the <u>Important Safety Information</u>. Before administration of Clariscan, read the <u>full Prescribing Information</u>, including <u>patient Medication Guide</u>.

2020 Coding and Reimbursement Guide

This 2020 Coding and Reimbursement Guide for Clariscan is intended to provide available current reimbursement information. In this document, coverage, coding, and payment for Clariscan are reviewed. In addition, the reimbursement services are described.

DISCLAIMER: All information included in this guide is for informational purposes only. It is intended to assist in the coding and reimbursement process. It represents no statement of guarantee by GE Healthcare. The existence of codes does not guarantee coverage of or payment for any procedure or contrast agent by any payer. The final decision for coding of any procedure must be made by the provider of care after considering the medical necessity of the services and supplies provided, as well as considering any regulations and local, state, or federal laws that may apply. All coding and reimbursement information is subject to change without notice, and specific payers may have their own coding and reimbursement requirements and policies. Please contact your local payer for interpretation of the appropriate codes to use for specific procedures.

Reference: 1. Clariscan [prescribing information]. Marlborough, MA: GE Healthcare; 2020.

Clariscan™ (gadoterate meglumine) injection for intravenous use

Basics of Coding

Healthcare providers and hospitals identify diseases, procedures, drugs, devices, and other healthcarerelated items provided to patients through various coding systems. Payers use the same coding systems to develop coverage policies and calculate payment for healthcare services.

Current Procedural Terminology (CPT) Codes

CPT codes describe the service and/or procedure being performed, not the outcomes achieved. Comparable procedures using different technologies are normally billed under the same CPT codes, unless there is a major distinction in the procedural technique associated with the products. The physician component of a CPT code is universal for all payers.

Healthcare Common Procedure Coding System (HCPCS)

The HCPCS is a standardized coding system used primarily to identify products, supplies and services, such as ambulance services and durable medical equipment, prosthetics, orthotics, and supplies, not included in the CPT codes.

National Drug Codes (NDCs)

NDCs are unique 10-digit numeric codes, composed of three segments, used to identify drugs. The first segment identifies the labeler (manufacturer), the second segment identifies the product, and the third segment identifies the packaging. Some payers will require 11-digit numeric codes.

Clariscan[™] gadoterate meglumine) injection for intravenous use

Basics of Coverage

The existence of CPT and HCPCS codes does not guarantee coverage. All payers have their own unique medical policies and guidelines. It is important that you review and adhere to each relevant payer policy.

Medicare

For procedures and products covered under Medicare Part B, coverage decisions are typically made through local coverage determinations (LCDs). LCDs are specific to the jurisdiction of a Medicare Administrative Contractor (MAC), meaning that the coverage policy or guideline would only apply to that MAC's jurisdiction. Therefore, coverage policies may vary by MAC.

Medicare also has the option to create a National Coverage Determination (NCD). All MACs must adhere to NCDs.

Commercial/Private Payers

Each commercial payer determines its own coverage policies. Commercial payers may implement restrictions and/or specific criteria. Coverage may also vary based on the patient's benefits or on the negotiated contract between the providers and the payer. Some payers have formal, published policies, but the lack of a published policy does not indicate noncoverage.

Medicaid

Each Medicaid program is administered by its particular state. That state determines its own specific coverage policies or guidelines. Some state Medicaid programs follow Medicare's policies, while others create their own. Some programs may implement restrictions and/or specific criteria. Medicaid coverage may also vary by provider type, setting of care, and the type of Medicaid plan the patient has (eg. fee-for-service, managed Medicaid).

Clariscan[™] gadoterate meglumine) injection for intravenous use

Basics of Payment

Payment is the amount that a payer renders to a healthcare entity for covered therapies and services. The payment methodology and amount vary based on where the care is provided.

The Centers for Medicare & Medicaid Services (CMS) sets a reimbursement amount for procedures, drugs, and/or supplies to allow for a uniform method of payment. The rates are set nationally, but adjustments are made to reflect the geographic differences in costs.

Physician Offices and Independent Diagnostic Testing Facilities (IDTFs)

Reimbursement for physician offices and IDTFs is based on the CPT code(s) used to report the service(s) provided. Medicare assigns each CPT code Relative Value Units (RVUs) which take into account the physician's work, practice expenses (overhead), and malpractice expenses associated with a procedure. The RVUs are then converted to a standard payment rate per procedure and are adjusted geographically.

Contrast agents are reimbursed in addition to the MRI procedure in this setting of care.

Hospital Outpatient Setting

In the hospital outpatient setting, the CPT codes are grouped into clinically homogeneous Ambulatory Payment Classifications (APCs) (Medicare only). Under APCs, hospitals are paid per encounter, and reimbursement is determined by the services and procedures provided as reported by the CPT code.

Contrast agents are not reimbursed in addition to the MRI procedure in this setting of care.

Clariscan[™] gadoterate meglumine) injection for intravenous use

2020 Coding and Reimbursement Information

To receive appropriate reimbursement, physicians should report the appropriate HCPCS code for the product along with the appropriate CPT code for the MRI procedure. Some payers may require the NDC for Clariscan.

Diagnosis and procedure coding are at the discretion of the physician, based on the clinical condition of the patient, the nature of the physician's findings, and the procedural steps dictated in the patient's medical record. Only the physician can determine a diagnosis. Because medical policies vary, verification of covered diagnosis is recommended.

Codes for MRI may include, but are not limited to:

CPT Code	Description
70552	MRI , brain with contrast material
70553	MRI, brain without contrast material, followed by contrast material(s) and further sequences
72142	MRI, spinal canal and contents, cervical; with contrast material
72147	MRI, spinal canal and contents, thoracic; with contrast material
72149	MRI, spinal canal and contents, lumbar; with contrast material
72156	MRI, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical
72157	MRI, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic
72158	MRI, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar

Clariscan[™] (gadoterate meglumine) injection for intravenous use

Please see <u>Product Indications and Important Safety Information About Clariscan</u>, including Boxed Warning, and the <u>full Prescribing Information</u>, including <u>patient Medication Guide</u>.

GE Confidential - Not for Discussion by the Sales Force

2020 Coding and Reimbursement Information (Cont'd)

Billing for Clariscan should always include the appropriate HCPCS code for the product along with the appropriate CPT code for the procedure. Commercial payers may require prior authorization for the procedure, and patient's physician will need to establish medical necessity for the procedure. In the hospital outpatient setting, Medicare will reimburse for both the CPT and HCPCS codes in one APC (Ambulatory Payment Classification) rate. Both codes may still be reported. Commercial payers will likely reimburse separately for each code, but this is contract dependent. We recommend a review of all contracts.

HCPS	
Code	Description
A9575	Injection, gadoterate meglumine, 0.1mL

National Drug Codes (NDCs)

NDCs are unique 10-digit-codes used to identify drugs. They are composed of three segments. The first segment identifies the labeler (manufacturer), the second segment identifies the product, and the third segment identifies the packaging. Some payers may require the NDC for Clariscan.

Some payers my require physicians to report an 11-digit-NDC when reporting a drug on a claim form. To convert the 10-digit code to an 11-digit code requires the inclusion of a leading zero in the labeler code section (first section) of the NDC.

Fill size	10 mL	15 mL	20 mL
NDC	0407-2943- 01	0407-2943- 02	0407-2943- 05

Please see <u>Product Indications and Important Safety Information About Clariscan</u>, including Boxed Warning, and the <u>full Prescribing Information</u>, including <u>patient Medication Guide</u>.

injection for intravenous use

Reimbursement in the Physician Office/IDTF Setting

In the physician office/IDTF setting, both the product and MRI enhanced by Clariscan may be reimbursed by Medicare. Commercial payers may also typically reimburse for both the product and MRI enhanced by Clariscan.

Reimbursement in the Hospital Outpatient Setting

Clariscan is not eligible for separate payment under the Medicare Hospital Outpatient Prospective Payment System (OPPS). Payment for Clariscan is combined with the payment for the MRI. Hospitals should still bill for the procedure and Clariscan.

Commercial payers may reimburse for both the product and MRI enhanced by Clariscan.

	Hospital Outpatient Department	Independent Diagnostic Testing Facilities
Medicare	APC (Ambulatory Payment Classification)	Per fee schedule, typically for each code
Medicare Advantage	Per contract, typically for each code	Per contract, typically for each code
Commercial	Per contract, typically for each code	Per contract, typically for each code

Clariscan[™] (gadoterate meglumine) injection for intravenous use

Support for Clariscan

GE Healthcare Reimbursement Support Line

GE Healthcare is pleased to offer toll-free customer support and documentation for coding and reimbursement related to our products. Please contact us at 800 767 6664.

Customer Service

To place an order, call 800 292 8514.

Medical Affairs

For technical or product-related questions and/or to reach a Clinical Applications Specialist, call 800 654 0118 (option 2, then option 3) or email medical.affairs@ge.com.

Please see <u>Product Indications and Important Safety Information About Clariscan</u>, including Boxed Warning, and the <u>full Prescribing Information</u>, including <u>patient Medication Guide</u>.

© 2020 General Electric Company GE, the GE Monogram, and Clariscan are trademarks of General Electric Company. Any third-party trademarks are the property of their respective owners.

June 2020 JB73440US(1)

Clariscan

(gadoterate meglumine)

injection for intravenous use

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use CLARISCAN safely and effectively. See full prescribing information for CLARISCAN.

CLARISCANTM (gadoterate meglumine) injection for intravenous use

Initial U.S. Approval: 2013

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF) See full prescribing information for complete boxed warning

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. • The risk for NSF appears highest among patients with:

- Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m²), or
 Acute kidney injury.
- Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing (<u>5.1</u>).

- RECENT MAJOR CHANGES-

4/2018

Warnings and Precautions, Gadolinium Retention (5.3)

· INDICATIONS AND USAGE -

Clariscan is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. $(\underline{1})$

----- DOSAGE AND ADMINISTRATION------

Adult and pediatric patients: The recommended dose of Clariscan is 0.2 mL/kg (0.1 mmol/kg) body weight administered as an intravenous bolus injection at a flow rate of approximately 2 mL/second for adults and 1-2 mL/second for pediatric patients. The dose is delivered by manual or power injection. (2)

FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)

- 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION
- **DOSAGE AND ADMINISTRATION** 2.1 Dosing Guidelines
- 2.2 Drug Handling
- DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS
- 5 WARNINGS AND PRECAUTIONS 5.1 Nephrogenic Systemic Fibrosis 5.2 Hypersensitivity Reactions 5.3 Gadolinium Retention 5.4 Acute Kidney Injury
- 5.5 Extravasation and Injection Site Reactions
 ADVERSE REACTIONS
 6.1 Clinical Studies Experience
- 6.2 Postmarketing Experience DRUG INTERACTIONS
- 8 USE IN SPECIFIC POPULATIONS
- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment

----- DOSAGE FORMS AND STRENGTHS -----

Clariscan Injection 0.5 mmol/mL contains 376.9 mg/mL of gadoterate meglumine and is available in vials. (3)

——— CONTRAINDICATIONS —

Clinically important hypersensitivity reactions to Clariscan. (4)
WARNINGS AND PRECAUTIONS

• Nephrogenic Systemic Fibrosis has occurred in patients with impaired elimination of GBCAs. Higher than recommended dosing or repeat dosing appear to increase the risk. (5.1)

• Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred. Monitor patients closely for need of emergency cardiorespiratory support. (5.2)

 \bullet Gadolinium is retained for months or years in brain, bone, and other organs. (5.3)

— ADVERSE REACTIONS —

The most frequent ($\geq 0.2\%$) adverse reactions in clinical studies were nausea, headache, injection site pain, injection site coldness, and rash. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact GE Healthcare at 1-800-654-0118 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pregnancy: Use only if imaging is essential during pregnancy and cannot be delayed. $(\underline{8.1})$

Additional pediatric use information is approved for Guerbet, LLC's Dotarem (gadoterate meglumine injection). However, due to Guerbet LLC's marketing exclusivity, this drug product is not labeled with that pediatric information.

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

CLINICAL PHARMACOLOGY

NONCLINICAL TOXICOLOGY

17.1 Nephrogenic Systemic Fibrosis

17.2 Common Adverse Reactions

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

13.2 Animal Toxicology and/or Pharmacology

PATIENT COUNSELING INFORMATION

HOW SUPPLIED/STORAGE AND HANDLING

*Sections or subsections omitted from the full prescribing information are not

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

CLINICAL STUDIES

17.3 General Precautions

OVERDOSAGE

DESCRIPTION

10 11

12

13

14

16

17

listed

Revised: 02/2020

FULL PRESCRIBING INFORMATION

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs.

- The risk for NSF appears highest among patients with:
 - Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m²), or
 - Acute kidney injury.
- Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing (5.1).
- For patients at highest risk for NSF, do not exceed the recommended Clariscan dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration [see Warnings and Precautions (5.1)].

1 INDICATIONS AND USAGE

Clariscan is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Additional pediatric use information is approved for Guerbet, LLC's Dotarem (gadoterate meglumine injection). However, due to Guerbet LLC's marketing exclusivity, this drug product is not labeled with that pediatric information.

2 DOSAGE AND ADMINISTRATION

2.1 Dosing Guidelines

For adult and pediatric patients, the recommended dose of Clariscan is 0.2 mL/kg (0.1 mmol/kg) body weight administered as an intravenous bolus injection, manually or by power injector, at a flow rate of approximately 2 mL/second for adults and 1-2 mL/second for pediatric patients. Table 1 provides weight-adjusted dose volumes.

Table 1: Volumes of Clariscan Injection by Body Weight

Body V	Body Weight		
Pounds (lb)	Kilograms (kg)	Milliliters (mL)	
22	10	2	
44	20	4	
66	30	6	
88	40	8	
110	50	10	
132	60	12	
154	70	14	
176	80	16	
198	90	18	
220	100	20	
242	110	22	
264	120	24	
286	130	26	
308	140	28	
330	150	30	

To ensure complete injection of Clariscan, the injection may be followed by normal saline flush. Contrast MRI can begin immediately following Clariscan injection.

Additional pediatric use information is approved for Guerbet, LLC's Dotarem (gadoterate meglumine injection). However, due to Guerbet LLC's marketing exclusivity, this drug product is not labeled with that pediatric information.

2.2 Drug Handling

- Visually inspect Clariscan for particulate matter prior to administration. Do not use the solution if particulate matter is present or if the container appears damaged. Clariscan should be a clear, colorless to yellow solution.
- Do not mix with other drugs or parenteral nutrition.
- Discard any unused portions of the drug.

Directions for Use of Clariscan (gadoterate meglumine) Injection

Glass vial:

Aseptically draw up the contrast medium into a disposable syringe and use immediately.

3 DOSAGE FORMS AND STRENGTHS

Clariscan 0.5 mmol/mL is a sterile, clear, colorless to yellow, aqueous solution for intravenous injection containing 376.9 mg/mL gadoterate meglumine and is available in vials.

4 CONTRAINDICATIONS

History of clinically important hypersensitivity reactions to Clariscan [see Warnings and Precautions (5.2)].

5 WARNINGS AND PRECAUTIONS

5.1 Nephrogenic Systemic Fibrosis

Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of GBCAs among these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities. The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR < 30 mL/min/1.73 m²) as well as patients with acute kidney injury. The risk appears lower for patients with chronic, moderate kidney disease (GFR 30 - 59 mL/min/1.73 m²) and little, if any, for patients with chronic, mild kidney disease (GFR 60 - 89 mL/min/1.73 m²). NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs.

Report any diagnosis of NSF following Clariscan administration to GE Healthcare at (1-800-654-0118) or FDA at (1-800-FDA-1088 or www.fda.gov/medwatch).

Screen patients for acute kidney injury and other conditions that may reduce renal function. Features of acute kidney injury consist of rapid (over hours to days), and usually reversible, decrease in kidney function, commonly in the setting of surgery, severe infection, injury or drug-induced kidney toxicity. Serum creatinine levels and estimated GFR may not reliably assess renal function in the setting of acute kidney injury. For patients at risk for chronically reduced renal function (e.g., age > 60 years, diabetes mellitus or chronic hypertension), estimate the GFR through laboratory testing.

The factors that may increase the risk for NSF are repeated or higher than recommended doses of a GBCA, and the degree of renal impairment at the time of exposure. Record the specific GBCA and the dose administered to a patient. For patients at highest risk for NSF, do not exceed the recommended Clariscan dose and allow a sufficient period of time for elimination of the drug prior to re-administration. For patients receiving hemodialysis, physicians may consider the prompt initiation of hemodialysis following the administration of a GBCA in order to enhance the contrast agent's elimination. The usefulness of hemodialysis in the prevention of NSF is unknown [see Dosage and Administration (2) and <u>Clinical Pharmacology (12)</u>].

5.2 Hypersensitivity Reactions

Anaphylactic and anaphylactoid reactions have been reported with gadoterate meglumine, involving cardiovascular, respiratory, and/or cutaneous manifestations. Some patients experienced circulatory collapse and died. In most cases, initial symptoms occurred within minutes of gadoterate meglumine administration and resolved with prompt emergency treatment [see Adverse Reactions (6)].

- Before Clariscan administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to Clariscan.
- Administer Clariscan only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, including personnel trained in resuscitation.
- During and following Clariscan administration, observe patients for signs and symptoms of hypersensitivity reactions.

5.3 Gadolinium Retention

Gadolinium is retained for months or years in several organs. The highest concentrations (nanomoles per gram of tissue) have been identified in the bone, followed by other organs (e.g. brain, skin, kidney, liver and spleen). The duration of retention also varies by tissue and is longest in bone. Linear GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses, gadolinium retention varies among the linear agents with Omniscan (gadodiamide) and Optimark (gadoversetamide) causing greater retention than other linear agents [Eovist (gadoxetate disodium), Magnevist (gadopentetate dimeglumine), MultiHance (gadobenate dimeglumine)]. Retention is lowest and similar among the macrocyclic GBCAs [Clariscan (gadoterate meglumine), Dotarem (gadoterate meglumine), Gadavist (gadobutrol), ProHance (gadoteridol)].

Consequences of gadolinium retention in the brain have not been established. Pathologic and clinical consequences of GBCA administration and retention in skin and other organs have been established in patients with impaired renal function [see Warnings and Precautions (5.1)]. There are rare reports of pathologic skin changes in patients with normal renal function. Adverse events involving multiple organ systems have been reported in patients with normal renal function without an established causal link to gadolinium retention [see Adverse Reactions (6.2)].

While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Consider the retention characteristics of the agent when choosing a GBCA for these patients. Minimize repetitive GBCA imaging studies, particularly closely spaced studies when possible.

5.4 Acute Kidney Injury

In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred with the use of GBCAs. The risk of acute kidney injury may increase with increasing dose of the contrast agent; administer the lowest dose necessary for adequate imaging. Screen all patients for renal impairment by obtaining a history and/or laboratory tests. Consider follow-up renal function assessments for patients with a history of renal dysfunction.

5.5 Extravasation and Injection Site Reactions

Ensure catheter and venous patency before the injection of Clariscan. Extravasation into tissues during Clariscan administration may result in tissue irritation [see Nonclinical Toxicology (13.2)].

6 ADVERSE REACTIONS

GBCAs have been associated with a risk for NSF [see Warnings and Precautions (5.1)]. Confirmed diagnosis of NSF has not been reported in patients with a clear history of exposure to gadoterate meglumine alone.

Hypersensitivity reactions and acute kidney injury are described in other sections of the labeling [see Warnings and Precautions (5.2) and (5.3)].

6.1 Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The data described below reflect gadoterate meglumine exposure in 2822 patients, representing 2682 adults and 140 pediatric patients. Overall, 55% of the patients were men. In clinical trials where ethnicity was recorded, the ethnic distribution was 74% Caucasian, 12% Asian, 4% Black, and 10% others. The average age was 53 years (range from < 1 week to 97 years).

Overall, 4% of patients reported at least one adverse reaction, primarily occurring immediately or within 24 hours following gadoterate meglumine administration. Most adverse reactions were mild or moderate in intensity and transient in nature.

Table 2 lists adverse reactions that occurred in $\geq 0.2\%$ patients who received gadoterate meglumine.

Table 2: Adverse Reactions in Clinical Trials

Reaction	Rate (%) n= 2867
Nausea	0.6%
Headache	0.4%
Injection Site Pain	0.4%
Injection Site Coldness	0.2%
Rash	0.2%

Adverse reactions that occurred with a frequency < 0.2% in patients who received gadoterate meglumine include: feeling cold, feeling hot, burning sensation, somnolence, pain, dizziness, dysgeusia, blood creatinine increased, hypotension, hypertension, asthenia, fatigue, injection site reactions (inflammation, extravasation, pruritus, swelling, warmth), paresthesia, pruritus, laryngeal discomfort, pain in extremity, vomiting, anxiety and palpitations.

Adverse Reactions in Pediatric Patients

During clinical trials, 140 pediatric patients (7 aged < 24 months, 33 aged 2 - 5 years, 57 aged 6 - 11 years and 43 aged 12 - 17 years) received gadoterate meglumine. Overall, 6 pediatric patients (4.3%) reported at least one adverse reaction following gadoterate meglumine administration. The most frequently reported adverse reaction was headache (1.1%). Most adverse events were mild in intensity and transient in nature.

Additional pediatric use information is approved for Guerbet, LLC's Dotarem (gadoterate meglumine injection). However, due to Guerbet LLC's marketing exclusivity, this drug product is not labeled with that pediatric information.

6.2 Postmarketing Experience

The following additional adverse reactions have been identified during postmarketing use of gadoterate meglumine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Table 3: Adverse Reactions in the Postmarketing Experience

System Organ Class	Adverse Reaction
Cardiac Disorders	bradycardia, tachycardia, arrhythmia
Immune System Disorders	hypersensitivity / anaphylactoid reactions including cardiac arrest, respiratory arrest, cyanosis, pharyngeal edema, laryngospasm, bronchospasm, angioedema, conjunctivitis, ocular hyperemia, eyelid edema, lacrimation increased, hyperhidrosis, urticaria
Nervous System Disorders	coma, convulsion, syncope, presyncope, parosmia, tremor
Musculoskeletal and Connective Tissue Disorders	muscle contracture, muscle weakness
Gastrointestinal Disorders	diarrhea, salivary hypersecretion
General Disorders and Administration Site Conditions	malaise, fever Adverse events with variable onset and duration have been reported after GBCA administration <i>[see Warnings and Precautions (5.3)]</i> . These include fatigue, asthenia, pain syndromes, and heterogeneous clusters of symptoms in the neurological, cutaneous, and musculoskeletal systems.
Skin and Subcutaneous Tissue Disorders	NSF, in patients whose reports were confounded by the receipt of other GBCAs or in situations where receipt of other GBCAs could not be ruled out. No unconfounded cases of NSF have been reported with gadoterate meglumine. Gadolinium-associated plaques.
Vascular Disorders	superficial phlebitis

7 DRUG INTERACTIONS

Gadoterate does not interfere with serum and plasma calcium measurements determined by colorimetric assays. Specific drug interaction studies with gadoterate meglumine have not been conducted.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. The human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive *(see Data)*. In animal reproduction studies, there were no adverse developmental effects observed in rats or rabbits with intravenous administration of gadoterate meglumine during organogenesis at doses up to 16 and 10 times, respectively, the recommended human dose *(see Data)*. Because of the potential risks of gadolinium to the fetus, use Clariscan only if imaging is essential during pregnancy and cannot be delayed.

The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Human Data

Contrast enhancement is visualized in the placenta and fetal tissues after maternal GBCA administration.

Cohort studies and case reports on exposure to GBCAs during pregnancy have not reported a clear association between GBCAs and adverse effects in the exposed neonates. However, a retrospective cohort study, comparing pregnant women who had a GBCA MRI to pregnant women who did not have an MRI, reported a higher occurrence of stillbirths and neonatal deaths in the group receiving GBCA MRI. Limitations of this study include a lack of comparison with non-contrast MRI and lack of information about the material indication for MRI. Overall, these data preclude a reliable evaluation of the potential risk of adverse fetal outcomes with the use of GBCAs in pregnancy.

Animal Data

Gadolinium Retention

GBCAs administered to pregnant non-human primates (0.1 mmol/kg on gestational days 85 and 135) result in measurable gadolinium concentration in the offspring in bone, brain, skin, liver, kidney, and spleen for at least 7 months. GBCAs administered to pregnant mice (2 mmol/kg daily on gestational days 16 through 19) result in measurable gadolinium concentrations in the pups in bone, brain, kidney, liver, blood, muscle, and spleen at one-month postnatal age.

Reproductive Toxicology

Gadoterate meglumine was administered in intravenous doses of 0, 2, 4 and 10 mmol/kg/day [3, 7 and 16 times the recommended human dose (RHD) based on body surface area (BSA)] to female rats for 14 days before mating, throughout the mating period and until gestation day (GD) 17. Pregnant rabbits were administered gadoterate meglumine in intravenous doses levels of 0, 1, 3 and 7 mmol/kg/day (3, 10 and 23 times the RHD based on BSA) from GD6 to GD19. No effects on embryo-fetal development were observed at doses up to 10 mmol/kg/day in rabbits. Maternal toxicity was observed in rats at 10 mmol/kg/day and in rabbits at 7 mmol/kg/day. This maternal toxicity was characterized in rats by a slightly lower litter size and gravid uterus weight compared to the control group, and in rabbits by a reduction in body weight and food consumption.

8.2 Lactation

Risk Summary

There are no data on the presence of gadoterate in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01 to 0.04% of the maternal gadolinium dose is present in breast milk. Additionally, there is limited GBCA gastrointestinal absorption in the breastfed infant. Gadoterate is present in goat milk (*see Data*). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Clariscan and any potential adverse effects on the breastfed infant from Clariscan or from the underlying maternal condition.

Data

Nonclinical data demonstrate that gadoterate is detected in goat milk in amounts < 0.1% of the dose intravenously administered. Furthermore, in rats, absorption of gadoterate via the gastrointestinal tract is poor (1.2% of the administered dose was absorbed and eliminated in urine).

8.4 Pediatric Use

The safety and efficacy of gadoterate meglumine at a single dose of 0.1 mmol/kg have been established in pediatric patients from 2 to 17 years of age based on clinical data in 133 pediatric patients 2 years of age and older. Adverse reactions in pediatric patients were similar to those reported in adults *[see Adverse Reactions (6.1)]*. No dosage adjustment according to age is necessary in pediatric patients *[See Dosage and Administration (2.1), Pharmacokinetics (12.3)]*. The safety of gadoterate meglumine has not been established in preterm neonates.

No cases of NSF associated with gadoterate meglumine or any other GBCA have been identified in pediatric patients age 6 years and younger *[see Warnings and Precautions (5.1)]*. Normal estimated GFR (eGFR) is approximately 30 mL/minute/1.73 m² at birth and increases to adult values by 2 years of age.

Juvenile Animal Data

Single and repeat-dose toxicity studies in neonatal and juvenile rats did not reveal findings suggestive of a specific risk for use in pediatric patients.

Additional pediatric use information is approved for Guerbet, LLC's Dotarem (gadoterate meglumine injection). However, due to Guerbet LLC's marketing exclusivity, this drug product is not labeled with that pediatric information.

8.5 Geriatric Use

In clinical studies of gadoterate meglumine, 900 patients were 65 years of age and over, and 304 patients were 75 years of age and over. No overall differences in safety or efficacy were observed between these subjects and younger subjects. In general, use of Clariscan in elderly patients should be cautious, reflecting the greater frequency of impaired renal function and concomitant disease or other drug therapy. No age-related dosage adjustment is necessary.

8.6 Renal Impairment

No Clariscan dosage adjustment is recommended for patients with renal impairment. Gadoterate meglumine can be removed from the body by hemodialysis [see <u>Warnings and Precautions (5.1)</u> and <u>Clinical Pharmacology (12.3)</u>].


10 OVERDOSAGE

Clariscan administered to healthy volunteers and to adult patients at cumulative doses up to 0.3 mmol/kg was tolerated in a manner similar to lower doses. Adverse reactions to overdosage with gadoterate meglumine have not been reported. Gadoterate meglumine can be removed from the body by hemodialysis [See Clinical Pharmacology (12.3)].

11 DESCRIPTION

Clariscan (gadoterate meglumine) is a paramagnetic macrocyclic ionic contrast agent administered for magnetic resonance imaging. The chemical name for gadoterate meglumine is D-glucitol, 1-deoxy-1-(methylamino)-, [1,4,7,10-tetraaceto(de-)-.kappa.N1, .kappa.N4, .kappa.N7, .kappa.N10, .kappa.O1, .kappa.O4, .kappa.O7, .kappa.O10]gadolinate(1-)(1:1); it has a formula weight of 753.9 g/mol and empirical formula of $C_{23}H_{42}O_{13}N_5Gd$ (anhydrous basis).

The structural formula of gadoterate meglumine in solution is as follows:



CAS Registry No. 92943-93-6

Clariscan Injection is a sterile, nonpyrogenic, clear, colorless to yellow, aqueous solution of 0.5 mmol/mL of gadoterate meglumine. Each vial contains 5 mmol per 10 mL, 7.5 mmol per 15 mL and 10 mmol per 20 mL. No preservative is added. Each mL of Clariscan contains 376.9 mg of gadoterate meglumine, 0.25 mg of DOTA and water for injection. Clariscan has a pH of 6.5 to 8.0.

The main physiochemical properties of Clariscan are provided below:

Table 4: Physicochemical Properties

Parameter	Value
Density @ 20°C	1.1753 g/cm ³
Viscosity @ 20 °C	3.4 mPa.s
Viscosity @ 37°C	2.4 mPa.s
Osmolality	1350 mOsm/kg water

The thermodynamic stability constants for gadoterate (log K_{therm} and log K_{cond} at pH 7.4) are 25.6 and 19.3, respectively.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Gadoterate is a paramagnetic molecule that develops a magnetic moment when placed in a magnetic field. The magnetic moment enhances the relaxation rates of water protons in its vicinity, leading to an increase in signal intensity (brightness) of tissues.

In magnetic resonance imaging (MRI), visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occurs with:

- 1) differences in proton density
- 2) differences of the spin-lattice or longitudinal relaxation times (T1)
- 3) differences in the spin-spin or transverse relaxation time (T2)

When placed in a magnetic field, gadoterate shortens the T1 and T2 relaxation times in target tissues. At recommended doses, the effect is observed with greatest sensitivity in the T1-weighted sequences.

12.2 Pharmacodynamics

Gadoterate affects proton relaxation times and consequently the MR signal, and the contrast obtained is characterized by the relaxivity of the gadoterate molecule. The relaxivity values for gadoterate are similar across the spectrum of magnetic field strengths used in clinical MRI (0.2-1.5 T).

Disruption of the blood-brain barrier or abnormal vascularity allows distribution of gadoterate in lesions such as neoplasms, abscesses, and infarcts.

12.3 Pharmacokinetics

The pharmacokinetics of total gadolinium assessed up to 48 hours following an intravenously administered 0.1 mmol/kg dose of gadoterate meglumine in healthy adult subjects demonstrated a mean elimination half-life (reported as mean \pm SD) of about 1.4 \pm 0.2 hours and 2.0 \pm 0.7 hours in female and male subjects, respectively. Similar pharmacokinetic profile and elimination half-life values were observed after intravenous injection of 0.1 mmol/kg of gadoterate meglumine followed 20 minutes later by a second injection of 0.2 mmol/kg (1.7 \pm 0.3 hours and 1.9 \pm 0.2 hours in female and male subjects, respectively).

Distribution

The volume of distribution at steady state of total gadolinium in normal subjects is 179 ± 26 and 211 ± 35 mL/kg in female and male subjects respectively, roughly equivalent to that of extracellular water. Gadoterate does not undergo protein binding *in vitro*. The extent of blood cell partitioning of gadoterate is not known.

Following GBCA administration, gadolinium is present for months or years in brain, bone, skin, and other organs [see *Warnings and Precautions (5.3)*].

Metabolism

Gadoterate is not known to be metabolized.

Elimination

Following a 0.1 mmol/kg dose of gadoterate meglumine, total gadolinium is excreted primarily in the urine with 72.9 \pm 17.0% and 85.4 \pm 9.7% (mean \pm SD) eliminated within 48 hours, in female and male subjects, respectively. Similar values were achieved after a cumulative dose of 0.3 mmol/kg (0.1 + 0.2 mmol/kg, 20 minutes later), with 85.5 \pm 13.2% and 92.0 \pm 12.0% recovered in urine within 48 hours in female and male subjects, respectively.

In healthy subjects, the renal and total clearance rates of total gadolinium are comparable $(1.27 \pm 0.32 \text{ and } 1.74 \pm 0.12 \text{ mL/min/kg} in females; and 1.40 \pm 0.31 \text{ and } 1.64 \pm 0.35 \text{ mL/min/kg} in males, respectively) indicating that the drug is primarily cleared through the kidneys. Within the studied dose range (0.1 to 0.3 mmol/kg), the kinetics of total gadolinium appear to be linear.$

Special Populations

Renal Impairment

A single intravenous dose of 0.1 mmol/kg of gadoterate meglumine was administered to 8 patients (5 men and 3 women) with impaired renal function (mean serum creatinine of $498 \pm 98 \ \mu$ mol/L in the 10-30 mL/min creatinine clearance group and $192 \pm 62 \ \mu$ mol/L in the 30-60 mL/min creatinine clearance group). Renal impairment delayed the elimination of total gadolinium. Total clearance decreased as a function of the degree of renal impairment. The distribution volume was unaffected by the severity of renal impairment (Table 5). No changes in renal function test parameters were observed after gadoterate meglumine injection. The mean cumulative urinary excretion of total gadolinium was approximately 76.9 \pm 4.5% in 48 hours in patients with moderate renal impairment, 68.4 \pm 3.5% in 72 hours in patients with severe renal impairment and 93.3 \pm 4.7% in 24 hours for subjects with normal renal function.

Table 5: Pharmacokinetic Profile of Total Gadolinium in Normal and Renally Impaired Patients

Population	Elimination Half- life (hr)	Plasma Clearance (L/h/kg)	Distribution Volume (L/kg)
Healthy volunteers	1.6 ± 0.2	0.10 ± 0.01	0.246 ± 0.03
Patients with moderate renal impairment	5.1 ± 1.0	0.036 ± 0.007	0.236 ± 0.01
Patients with severe renal impairment	13.9 ± 1.2	0.012 ± 0.001	0.234 ± 0.01

Gadoterate was shown to be dialyzable after an IV injection of gadoterate meglumine in 10 patients with end-stage renal failure who required hemodialysis treatment. Gd serum concentration decreased over time by 88%, 93% and 97% at 0.5 hours, 1.5 hours, and 4 hours after start of dialysis, respectively. A second and third hemodialysis session further removed Gd. After the third dialysis, Gd serum concentration decreased by 99.7%.

Pediatric Population

Additional pediatric use information is approved for Guerbet, LLC's Dotarem (gadoterate meglumine injection). However, due to Guerbet LLC's marketing exclusivity, this drug product is not labeled with that pediatric information.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal studies have not been performed to evaluate the carcinogenic potential of gadoterate meglumine.

Gadoterate meglumine did not demonstrate mutagenic potential in *in vitro* bacterial reverse mutation assays (Ames test) using Salmonella typhimurium, in an *in vitro* chromosome aberration assay in Chinese hamster ovary cells, in an *in vitro* gene mutation assay in Chinese hamster lung cells, nor in an *in vivo* mouse micronucleus assay.

No impairment of male or female fertility and reproductive performance was observed in rats after intravenous administration of gadoterate meglumine at the maximum tested dose of 10 mmol/kg/day (16 times the maximum human dose based on surface area), given during more than 9 weeks in males and more than 4 weeks in females. Sperm counts and sperm motility were not adversely affected by treatment with the drug.

13.2 Animal Toxicology and/or Pharmacology

Local intolerance reactions, including moderate irritation associated with infiltration of inflammatory cells were observed after perivenous injection in rabbits suggesting the possibility of local irritation if the contrast medium leaks around the veins in a clinical setting [see Warnings and Precautions (5.5)].

Toxicity of gadoterate meglumine was evaluated in neonatal and juvenile (pre- and post-weaning) rats following a single or repeated intravenous administration at doses 1, 2, and 4 times the MHD based on BSA. Gadoterate meglumine was well tolerated at all dose levels tested and had no effect on growth, pre-weaning development, behavior and sexual maturation.

14 CLINICAL STUDIES

CNS Imaging

Efficacy and safety of gadoterate meglumine were evaluated in a multi-center clinical trial (Study A) that enrolled 364 adult and 38 pediatric patients (aged ≥ 2 years) with known or suspected CNS lesions. Adults were randomized 2 to 1 to receive either gadoterate meglumine or gadopentetate dimeglumine, each administered at a dose of 0.1 mmol/kg. All pediatric patients received gadoterate meglumine, also at a dose of 0.1 mmol/kg. In the trial, patients first underwent a baseline (pre-contrast) MRI examination followed by the assigned GBCA administration and a post-contrast MR examination. The images (pre-contrast, post-contrast and "paired pre- and post-contrast") were interpreted by three independent off-site readers blinded to clinical information. The primary efficacy analysis compared three patient-level visualization scores (paired images) to baseline MRI (pre-contrast images) for adults who received gadoterate meglumine. The three primary visualization components were: contrast enhancement, border delineation and internal morphology. For each of these components there was a pre-defined scoring scale. Lesion counting (up to five per patient) was also reflected within each component's patient-level visualization score.

Among the adult patients, 245 received gadoterate meglumine and their data comprised the primary efficacy population. There were 114 (47%) men and 131 (53%) women with a mean age of 53 years (range 18 to 85 years), the racial and ethnic representations were 84% Caucasian, 11% Asian, 4% Black, and 1% other.

Table 6 displays a comparison of paired images (pre-and post-contrast) to pre-contrast images with respect to the proportion of patients who had paired image scores that were greater "better", or same/worse "not better" than the pre-contrast scores and with respect to the difference in the mean patient level visualization score. Across the three readers 56% to 94% of patients had improved lesion visualization for paired images compared to pre-contrast images. Gadoterate meglumine provided a statistically significant improvement for all three primary visualization components. More lesions were seen on the paired images than the pre-contrast images.

Table 6: Study A. Improvement in Patient-level Lesion Visualization Scores, Paired versus Pre-contrast Images^(a)

I	Reader 1	Reader 2	Reader 3
Lesion Scores	n = 231	n = 232	n = 237
Border Delineation			
Better	195 (84%)	215 (93%)	132 (56%)
Not Better	28 (12%)	7 (3%)	88 (37%)
Missing	8 (4%)	10 (4%)	17 (7%)
Difference in Mean Score ^(b)	2.26*	2.89*	1.17*
Internal Morphology			
Better	218 (94%)	214 (93%)	187 (79%)
Not Better	5 (2%)	8 (3%)	33 (14%)
Missing	8 (4%)	10 (4%)	17 (7%)
Difference in Mean Score ^(b)	2.74*	2.75*	1.54*
Contrast Enhancement	l I		1
Better	208 (90%)	216 (93%)	208 (88%)
Not Better	15 (6%)	6 (3%)	12 (5%)
Missing	8 (4%)	10 (4%)	17 (7%)
Difference in Mean Score ^(b)	3.09*	3.69*	2.92*

^(a) Better: number of patients with paired (pre-and post-contrast) score greater than the pre-contrast score Not better: number of patients with paired score same as or worse than the pre-contrast score Missing: number of patients with missing score

^(b) Difference = paired mean score minus pre-contrast mean score

*Statistically significant improvement by paired t-test

In secondary analyses, post-contrast images were improved in comparison to pre-contrast images. Gadoterate meglumine lesion visualization scores were similar to those for gadopentetate dimeglumine. Gadoterate meglumine imaging results in the pediatric patients were also similar to those seen in adults.

In a second clinical trial (Study B), MR images were reread from 150 adult patients with known CNS lesions who had participated in a previously conducted clinical trial. Gadoterate meglumine administration and image interpretation was performed in the same manner as in Study A. Similar to Study A, this trial also demonstrated improved lesion visualization with gadoterate meglumine.

Additional pediatric use information is approved for Guerbet, LLC's Dotarem (gadoterate meglumine injection). However, due to Guerbet LLC's marketing exclusivity, this drug product is not labeled with that pediatric information.

16 HOW SUPPLIED/STORAGE AND HANDLING

Clariscan Injection is a clear, colorless to yellow solution containing 0.5 mmol/mL of gadoterate meglumine. It is supplied in vials.

• Clariscan Injection is supplied in 10 mL vials containing 10 mL of solution and in 20 mL vials containing 15 mL or 20 mL of solution.

Each single-dose vial is closed with a rubber stopper and sealed with an aluminum cap and the contents are sterile. Vials are individually packaged in a package of 10, in the following configurations:

5 mmol per 10 mL (0.5 mmol per mL) in glass vial (NDC 0407-2943-01) 7.5 mmol per 15 mL (0.5 mmol per mL) in glass vial (NDC 0407-2943-02) 10 mmol per 20 mL (0.5 mmol per mL) in glass vial (NDC 0407-2943-05) Storage

Sionage	MEDICATION GUIDE
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP, Controlled Room Temperature].	CLARISCAN [™] (kla-ri'-skan)
Should solidification occur in the vial because of exposure to the cold, bring Clariscan to room temperature before use. If	(gadoterate meglumine)
allowed to stand at room temperature for a minimum of 90 minutes, Clariscan should return to a clear, colorless to yellow	injection for intravenous use
solution. Before use, examine the product to assure that all solids are dissolved and that the container and closure have not	What is Clariscan?
been damaged. Discard the vial if solids persist.	Clariscan is a prescription medicine called a gadolinium-based contrast agent (GBCA). Clariscan, like other GBCAs, is injected into
17 PATIENT COUNSELING INFORMATION	 your vein and used with a magnetic resonance imaging (MRI) scanner. An MRI exam with a GBCA, including Clariscan, helps your doctor to see problems better than an MRI exam without a GBCA.
	 Your doctor has reviewed your medical records and has determined that you would benefit from using a GBCA with your MRI exam.
 Advise the patient to read the FDA-approved patient labeling (Medication Guide) 	
	What is the most important information I should know about Clariscan?
17.1 Nephrogenic Systemic Fibrosis	• Clariscan contains a metal called gadolinium. Small amounts of gadolinium can stay in your body including the brain, bones, skin
Instruct patients to inform their healthcare provider if they:	 and other parts of your body for a long time (several months to years). It is not known how gadolinium may affect you, but so far, studies have not found harmful effects in patients with normal kidneys.
1. have a history of kidney disease, or	 Rarely patients have reported pains, tiredness, and skin, muscle or bone ailments for a long time, but these symptoms have not been
2. have recently received a GBCA.	directly linked to gadolinium.
	• There are different GBCAs that can be used for your MRI exam. The amount of gadolinium that stays in the body is different
GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. To counsel patients at risk for	for different gadolinium medicines. Gadolinium stays in the body more after Omniscan or Optimark than after Eovist, Magnevist or MultiHance. Gadolinium stays in the body the least after Clariscan, Dotarem, Gadavist or ProHance.
NSF:	 People who get many doses of gadolinium medicines, women who are pregnant and young children may be at increased risk from
Describe the clinical manifestations of NSF.Describe procedures to screen for the detection of renal impairment.	gadolinium staying in the body.
• Describe procedures to screen for the detection of renar impairment.	• Some people with kidney problems who get gadolinium medicines can develop a condition with severe thickening of the skin,
Instruct the patients to contact their physician if they develop signs or symptoms of NSF following Clariscan	muscles and other organs in the body (nephrogenic systemic fibrosis). Your healthcare provider should screen you to see how well your kidneys are working before you receive Clariscan.
administration, such as burning, itching, swelling, scaling, hardening and tightening of the skin; red or dark patches on the	
skin; stiffness in joints with trouble moving, bending or straightening the arms, hands, legs or feet; pain in the hip bones	Do not receive Clariscan if you have had a severe allergic reaction to Clariscan.
or ribs; or muscle weakness.	Before receiving Clariscan, tell your healthcare provider about all your medical conditions, including if you:
	• have had any MRI procedures in the past where you received a GBCA. Your healthcare provider may ask you for more information
17.2 Common Adverse Reactions	including the dates of these MRI procedures.
Inform patients that they may experience:	 are pregnant or plan to become pregnant. It is not known if Clariscan can harm your unborn baby. Talk to your healthcare provider about the possible risks to an unborn baby if a GBCA such as Clariscan is received during pregnancy.
	 have kidney problems, diabetes, or high blood pressure.
• Reactions along the venous injection site, such as mild and transient burning or pain or feeling of warmth or	• have had an allergic reaction to dyes (contrast agents) including GBCA.
coldness at the injection site.	
 Side effects of headache, nausea, abnormal taste and feeling hot. 	What are possible side effects of Clariscan?
	See "What is the most important information I should know about Clariscan?" Allergie reactions. Clariscan can say allergie reactions that can sometimes be serious. Your healthcare provider will meniter
17.3 General Precautions	• Allergic reactions. Clariscan can cause allergic reactions that can sometimes be serious. Your healthcare provider will monitor you closely for symptoms of an allergic reaction.
• Pregnancy: Advise pregnant women of the potential risk of fetal exposure to gadoterate [see Use in Specific]	The most common side effects of Clariscan include: nausea, headache, pain, or cold feeling at the injection site, and rash.
<u>Population (8.1)]</u>	These are not all the possible side effects of Clariscan.
• Gadolinium Retention: Advise patients that gadolinium is retained for months or years in brain, bone, skin, and other	Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
organs in patients with normal renal function. The clinical consequences of retention are unknown. Retention	General information about the safe and effective uses of Clariscan.
depends on multiple factors and is greater following administration of linear GBCAs than following administration	Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your healthcare provider for
of macrocyclic GBCAs [see Warnings and Precautions (5.3)].	information about Clariscan that is written for health professionals.
Rx Only	What are the ingredients in Clariscan? Active ingredient: gadoterate meglumine
GE Healthcare	Inactive ingredients: DOTA, water for injection
Distributed by GE Healthcare Inc.	Manufactured by: GE Healthcare AS Oslo, Norway GE and the GE Monogram are trademarks of General Electric Company.
Marlborough, MA 01752 U.S.A.	For more information, go to <u>www.GEHealthcare.com</u> or call 1-800-654-0118.
Product of Norwegian Origin.	
GE and the GE Monogram are trademarks of General Electric Company.	This Medication Guide has been approved by the U.S. Food and Drug Administration.11/2019
1197884 BK	